AUTL - Autolus Therapeutics Announces Changes to its Board of Directors | Benzinga
- Appointment of Elisabeth ("Lis") Leiderman, M.D.
- Resignation of Kapil Dhingra, M.D.
LONDON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Elisabeth Leiderman, M.D. to the Board of Directors. Additionally, the Company announced that Kapil Dhingra M.D., who has served on Autolus' Board of Directors since May 2015, has advised the Board of his intent to step down from his role as a member of the Board and chair of the Nominating and Corporate Governance Committee of the Board, effective December 31, 2023.
"The Autolus Board and Management Team would like to welcome Lis Leiderman to the Board of Directors. Lis brings a wealth of financial, transaction and operational experience to the Company," said Dr. Christian Itin, Chief Executive Officer of Autolus. "We would also like to thank Kapil for his invaluable advice on development and strategy since the inception of Autolus and we wish him well with his new projects. We have recently submitted a Biologics License Application (BLA) for obe-cel to the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) and look forward to transforming Autolus from a development stage to a commercial company."
Dr. Leiderman has more than 15 years of expertise in business development, strategy, and finance in the life sciences industry. She most recently served as Chief Financial Officer & Chief Business Officer at Atsena Therapeutics. Prior to joining Atsena, she was Chief Financial Officer and Head of ...